WuXi Biologics to Invest $389 Million in New Biomanufacturing Facility

May 03, 2018
By BioPharm International Editors

On April 30, 2018, WuXi Biologics, part of WuXi AppTech, announced plans to invest EUR 325 million (US$389 million) in a new biomanufacturing facility in Mullagharlin, Dundalk, County Louth, Ireland.

According to the company, the new facility will use multiple single-use bioreactors for commercial biomanufacturing and is designed to be able to run continuous bioprocessing. A total of 48,000 L fed-batch and 6,000 L perfusion bioreactor capacity will also be installed.

The site will be on a 26-hectare campus and is the company’s first site outside of China. The investment is expected to create over 400 skilled jobs over a five-year span, as well as add approximately 700 construction jobs.

The project is supported by the Irish Government through IDA Ireland, an economic development body for Ireland.

Source: WuXi Biologics

native1_300x100
lorem ipsum